A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier of Huntington disease age-at-onset in a large european cohort

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Weydt, Patrick ^a   Soyal, Selma M ^b   Landwehrmeyer, G B ^a   Patsch, Wolfgang ^b  

^a UNIVERSITY OF ULM   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Gender effect; Genetic modifier; Huntington disease; Neurodegeneration

Indexed keywords

METHIONINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; THREONINE; PPARGC1A PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

AMINO ACID SUBSTITUTION; ARTICLE; CAG REPEAT; CELL RESPIRATION; CONTROLLED STUDY; EUROPE; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MODIFIER GENE; ONSET AGE; SINGLE NUCLEOTIDE POLYMORPHISM; COHORT ANALYSIS; FEMALE; GENETICS; HUNTINGTON DISEASE; OPEN READING FRAME; REGISTER;

AGE OF ONSET; COHORT STUDIES; EUROPE; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; OPEN READING FRAMES; POLYMORPHISM, SINGLE NUCLEOTIDE; REGISTRIES; TRANSCRIPTION FACTORS;

EID: 84891593032     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-1     Document Type: Article

References (34)

1. Arning L, Epplen JT. Genetic modifiers of Huntington's disease: beyond CAG. Future Neurol 2012, 7:93-109.
2. Gusella JF, MacDonald ME. Huntington's disease: the case for genetic modifiers. Genome Med 2009, 1:80. 10.1186/gm80, 2768966, 19725930.
3. Lin J, Wu P-H, Tarr PT, Lindenberg KS, St-Pierre J, Zhang C-Y, Mootha VK, Jäger S, Vianna CR, Reznick RM, Cui L, Manieri M, Donovan MX, Wu Z, Cooper MP, Fan MC, Rohas LM, Zavacki AM, Cinti S, Shulman GI, Lowell BB, Krainc D, Spiegelman BM. Defects in Adaptive Energy Metabolism with CNS-Linked Hyperactivity in PGC-1α Null Mice. Cell 2004, 119:121-135. 10.1016/j.cell.2004.09.013, 15454086.
4. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP. PGC-1α Deficiency Causes Multi-System Energy Metabolic Derangements: Muscle Dysfunction Abnormal Weight Control and Hepatic Steatosis. Plos Biol 2005, 3:e101. 10.1371/journal.pbio.0030101, 1064854, 15760270.
5. Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet IR, Schwartz MW, La Spada AR. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration. Cell Metab 2006, 4:349-362. 10.1016/j.cmet.2006.10.004, 17055784.
6. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration. Cell 2006, 127:59-69. 10.1016/j.cell.2006.09.015, 17018277.
7. Szalardy L, Zadori D, Plangar I, Vecsei L, Weydt P, Ludolph A, Klivényi P, Kovacs G. Neuropathology of partial PGC-1α deficiency recapitulates features of mitochondrial encephalopathies but not of neurodegenerative diseases. Neurodegener Dis 2012, 1-22.
8. Handschin C. The biology of PGC-1α and its therapeutic potential. Trends Pharmacol Sci 2009, 30:322-329. 10.1016/j.tips.2009.03.006, 19446346.
9. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998, 92:829-839. 10.1016/S0092-8674(00)81410-5, 9529258.
10. Esterbauer H, Oberkofler H, Krempler F, Patsch W. Human Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 (PPARGC1) Gene: cDNA Sequence, Genomic Organization, Chromosomal Localization, and Tissue Expression. Genomics 1999, 62:98-102. 10.1006/geno.1999.5977, 10585775.
11. Soyal S, Krempler F, Oberkofler H, Patsch W. PGC-1α: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes. Diabetologia 2006, 49:1477-1488. 10.1007/s00125-006-0268-6, 16752166.
12. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet J-C, Scherzer CR. PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson's Disease. Sci Transl Med 2010, 2:52ra73. 3129986, 20926834.
13. Eschbach J, Schwalenstocker B, Soyal SM, Bayer H, Wiesner D, Akimoto C, Nilsson AC, Birve A, Meyer T, Dupuis L, Danzer KM, Andersen PM, Witting A, Ludolph AC, Patsch W, Weydt P. PGC-1α is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum Mol Genet 2013, 22:3477-3484. 10.1093/hmg/ddt202, 23669350.
14. Róna-Vörös K, Weydt P. The role of PGC-1α in the pathogenesis of neurodegenerative disorders. Curr Drug Targets 2010, 11:1262-1269. 10.2174/1389450111007011262, 20840068.
15. Soyal SM, Felder TK, Auer S, Hahne P, Oberkofler H, Witting A, Paulmichl M, Landwehrmeyer GB, Weydt P, Patsch W, For the European Huntington Disease Network A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset. Hum Mol Genet 2012, 21:3461-3473. 10.1093/hmg/dds177, 22589246, For the European Huntington Disease Network.
16. Weydt P, Soyal S, Gellera C, DiDonato S, Weidinger C, Oberkofler H, Landwehrmeyer G, Patsch W. The gene coding for PGC-1α modifies age at onset in Huntington's Disease. Mol Neurodegener 2009, 4:3. 10.1186/1750-1326-4-3, 2630305, 19133136.
17. Taherzadeh-Fard E, Saft C, Andrich J, Wieczorek S, Arning L. PGC-1α as modifier of onset age in Huntington disease. Mol Neurodegener 2009, 4:10. 10.1186/1750-1326-4-10, 2644307, 19200361.
18. Che HVB, Metzger S, Portal E, Deyle C, Riess O, Nguyen HP. Localization of sequence variations in PGC-1α influence their modifying effect in Huntington disease. Mol Neurodegener 2011, 6:1. 10.1186/1750-1326-6-1, 3022537, 21211002.
19. Chen Y, Brew B. Characterization of the kynurenine pathway in nsc 34 cell line: implications for amyotrophic lateral sclerosis. J Neurochem
20. Taherzadeh-Fard E, Saft C, Akkad DA, Wieczorek S, Haghikia A, Chan A, Epplen JT, Arning L. PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease. Mol Neurodegener 2011, 6:32. 10.1186/1750-1326-6-32, 3117738, 21595933.
21. Orth M, The European Huntington 's Disease Network Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. J Neurol Neurosurg Psychiatry 2011, 82:1409-1412. 10.1136/jnnp.2010.209668, 21097549, The European Huntington 's Disease Network.
22. Lee J-M, Ramos EM, Lee J-H, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJA, Mccusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 2012, 78:690-695. 10.1212/WNL.0b013e318249f683, 3306163, 22323755.
23. Ruas JL, White JP, Rao RR, Kleiner S, Brannan KT, Harrison BC, Greene NP, Wu J, Estall JL, Irving BA, Lanza IR, Rasbach KA, Okutsu M, Nair KS, Yan Z, Leinwand LA, Spiegelman BM. A PGC-1α Isoform Induced by Resistance Training Regulates Skeletal Muscle Hypertrophy. Cell 2012, 151:1319-1331. 10.1016/j.cell.2012.10.050, 3520615, 23217713.
24. Combet C, Blanchet C, Geourjon C, Deléage G. NPS@: network protein sequence analysis. Trends Biochem Sci 2000, 25:147-150. 10.1016/S0968-0004(99)01540-6, 10694887.
25. Nitz I, Ewert A, Klapper M, Döring F. Analysis of PGC-1α variants Gly482Ser and Thr612Met concerning their PPARγ2-coactivation function. Biochem Biophys Res Commun 2007, 353:481-486. 10.1016/j.bbrc.2006.12.042, 17187763.
26. SanGiovanni JP, Chen J, Sapieha P, Aderman CM, Stahl A, Clemons TE, Chew EY, Smith LEH. DNA Sequence Variants in PPARGC1A, a Gene Encoding a Coactivator of the ω-3 LCPUFA Sensing PPAR-RXR Transcription Complex Are Associated with NV AMD and AMD-Associated Loci in Genes of Complement and VEGF Signaling Pathways. PLoS ONE 2013, 8:e53155. 10.1371/journal.pone.0053155, 3546058, 23335958.
27. Zielonka D, Marinus J, Roos RAC, De Michele G, Di Donato S, Putter H, Marcinkowski J, Squitieri F, Bentivoglio AR, Landwehrmeyer GB. The influence of gender on phenotype and disease progression in patients with Huntington's disease. Parkinsonism Relat Disord 2012, 1-6.
28. Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS ONE 2007, 2:647.
29. Bode FJ, Stephan M, Suhling H, Pabst R, Straub RH, Raber KA, Bonin M, Nguyen H-P, Riess O, Bauer A, Sjoberg C, Petersen A, Horsten Von S. Sex differences in a transgenic rat model of Huntington's disease: decreased 17 -estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Hum Mol Genet 2008, 17:2595-2609. 10.1093/hmg/ddn159, 18502785.
30. Kehoe P, Krawczak M, Harper PS, Owen MJ, Jones AL. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet 1999, 36:108-111. 1734310, 10051007.
31. Arning L, Saft C, Wieczorek S, Andrich J, Kraus PH, Epplen JT. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet 2007, 122:175-182. 10.1007/s00439-007-0393-4, 17569088.
32. Saft C. Apolipoprotein E genotypes do not influence the age of onset in Huntington's disease. J Neurol Neurosurg Psychiatry 2004, 75:1692-1696. 10.1136/jnnp.2003.022756, 1738834, 15548484.
33. Andresen JM, Gayan J, Cherny SS, Brocklebank D, Alkorta-Aranburu G, Addis EA, Cardon LR, Housman DE, Wexler NS, The US-Venezuela Collaborative Research Group Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J Med Genet 2006, 44:44-50. 10.1136/jmg.2006.045153, 2597910, 17018562, The US-Venezuela Collaborative Research Group.
34. Jazin E, Cahill L. Sex differences in molecular neuroscience: from fruit flies to humans. Nat Rev Neurosci 2010, 11:9-17.